NL9201440A - Triantennaire clusterglycosiden, hun bereiding en toepassing. - Google Patents

Triantennaire clusterglycosiden, hun bereiding en toepassing. Download PDF

Info

Publication number
NL9201440A
NL9201440A NL9201440A NL9201440A NL9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A
Authority
NL
Netherlands
Prior art keywords
group
glycoside
formula
residue
compound
Prior art date
Application number
NL9201440A
Other languages
English (en)
Dutch (nl)
Original Assignee
Univ Leiden
Nl Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Nl Hartstichting filed Critical Univ Leiden
Priority to NL9201440A priority Critical patent/NL9201440A/nl
Priority to AU48355/93A priority patent/AU674160B2/en
Priority to DK93921124T priority patent/DK0655070T3/da
Priority to DE69319912T priority patent/DE69319912T2/de
Priority to JP6506123A priority patent/JPH08502726A/ja
Priority to US08/382,022 priority patent/US5885968A/en
Priority to AT93921124T priority patent/ATE168694T1/de
Priority to ES93921124T priority patent/ES2122041T3/es
Priority to PCT/NL1993/000169 priority patent/WO1994004545A1/fr
Priority to EP93921124A priority patent/EP0655070B1/fr
Publication of NL9201440A publication Critical patent/NL9201440A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NL9201440A 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing. NL9201440A (nl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU48355/93A AU674160B2 (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
DK93921124T DK0655070T3 (da) 1992-08-11 1993-08-11 Triantennære klusterglycosider, deres fremstilling og anvendelse
DE69319912T DE69319912T2 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
JP6506123A JPH08502726A (ja) 1992-08-11 1993-08-11 ３分枝性クラスタグリコシドの調製およびその用途
US08/382,022 US5885968A (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
AT93921124T ATE168694T1 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
ES93921124T ES2122041T3 (es) 1992-08-11 1993-08-11 Glicosidos triantenarios aglomerados, su preparacion y utilizacion.
PCT/NL1993/000169 WO1994004545A1 (fr) 1992-08-11 1993-08-11 Glycosides en agglomerat triantennaires, leur preparation et utilisation
EP93921124A EP0655070B1 (fr) 1992-08-11 1993-08-11 Glycosides en agglomerat triantennaires, leur preparation et utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
NL9201440 1992-08-11

Publications (1)

Publication Number Publication Date
NL9201440A true NL9201440A (nl) 1994-03-01

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Country Status (10)

Country Link
US (1) US5885968A (fr)
EP (1) EP0655070B1 (fr)
JP (1) JPH08502726A (fr)
AT (1) ATE168694T1 (fr)
AU (1) AU674160B2 (fr)
DE (1) DE69319912T2 (fr)
DK (1) DK0655070T3 (fr)
ES (1) ES2122041T3 (fr)
NL (1) NL9201440A (fr)
WO (1) WO1994004545A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821001A4 (fr) * 1995-03-31 2002-07-17 Drug Delivery System Inst Ltd Derives d'amidite et derives d'oligonucleotides
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
BR112014004585A2 (pt) 2011-08-26 2017-06-13 Arrowhead Res Corp polímeros de poli(éster vinílico) para liberação de ácido nucleico in vivo
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
CN104837996A (zh) 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
WO2014118272A1 (fr) 2013-01-30 2014-08-07 Santaris Pharma A/S Conjugués glucidiques d'oligonucléotides antimir-22
CA2893801A1 (fr) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Conjugues glucidiques d'oligonucleotides d'acides nucleiques bloques
EP3591054A1 (fr) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Oligomères et conjugués antisens ciblant pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CN108064313B (zh) 2015-03-17 2021-07-30 箭头药业股份有限公司 用于抑制因子xii的基因表达的组合物和方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
UY37146A (es) 2016-03-07 2017-09-29 Arrowhead Pharmaceuticals Inc Ligandos de direccionamiento para compuestos terapéuticos
CR20180432A (es) 2016-03-14 2018-11-21 Hoffmann La Roche Oligonucleótidos para reducir la expresión de pd-l1
EP3228326A1 (fr) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Acide nucléique lié à un glycoconjugué trivalent
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
KR102557906B1 (ko) 2016-09-02 2023-07-20 애로우헤드 파마슈티컬스 인코포레이티드 표적화 리간드
US10450565B2 (en) 2017-01-10 2019-10-22 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
WO2018185252A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Conjugués d'acides nucléiques
EP3483269A1 (fr) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
WO2018185241A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Produits et compositions
EP3385380A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produits et compositions
EP3385381A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Produits et compositions
EP3550022A1 (fr) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produits et compositions
EP4219714A3 (fr) 2017-04-05 2023-08-30 Silence Therapeutics GmbH Inhibition de tmprss6 induite par interférence arn
WO2018185253A1 (fr) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Acides nucléiques bicaténaires modifiés par un ligand
EP3385272A1 (fr) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Nouveaux conjugués de ligand d'oligonucléotide
US11414660B2 (en) 2017-04-05 2022-08-16 Silence Therapeutics Gmbh Products and compositions
CN111107853A (zh) 2017-09-11 2020-05-05 箭头药业股份有限公司 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
TN2020000038A1 (en) 2017-09-14 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
KR102431353B1 (ko) 2017-10-16 2022-08-10 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
EP3697909A4 (fr) 2017-10-17 2021-10-13 Arrowhead Pharmaceuticals, Inc. Agents à base d'arni et compositions destinées à inhiber l'expression du récepteur 1 de l'asialoglycoprotéine
MA51707A (fr) 2017-11-13 2020-09-23 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression d'un gène cible comprenant des liaisons phosphorodithioate
EP3483270A1 (fr) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
RS63955B1 (sr) 2017-11-13 2023-02-28 Silence Therapeutics Gmbh Nukleinske kiseline za inhibiciju ekspresije lpa u ćeliji
CA3118327A1 (fr) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Acides nucleiques permettant d'inhiber l'expression de l'aldh2 dans une cellule
EP3550021A1 (fr) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Produits et compositions pour l'inhibition d'expression d'un gène cible
EP3775207A1 (fr) 2018-04-05 2021-02-17 Silence Therapeutics GmbH Siarns avec vinylphosphonate à l'extrémité 5' du brin antisens
WO2020007892A1 (fr) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucléotides pour moduler l'expression de tau
EP3598995A1 (fr) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produits et compositions
EP3844274A1 (fr) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Manipulation de néoantigène à l'aide de composés de modulation d'épissage
PL3880818T3 (pl) 2018-11-13 2023-01-23 Silence Therapeutics Gmbh Kwasy nukleinowe do hamowania ekspresji LPA w komórce
EP3730617A1 (fr) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression de c3 dans une cellule
US20220017899A1 (en) 2018-11-23 2022-01-20 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
JP2022521155A (ja) 2019-02-07 2022-04-06 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
WO2020173845A1 (fr) 2019-02-26 2020-09-03 Roche Innovation Center Copenhagen A/S Procédé de formulation d'oligonucléotides
JP2022531874A (ja) 2019-05-07 2022-07-12 ウニベルジテート ベルン 細胞におけるｐｒｏｓ１の発現を阻害するための核酸
US20220305046A1 (en) 2019-06-06 2022-09-29 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
BR112022003513A2 (pt) 2019-08-27 2022-05-17 Silence Therapeutics Gmbh Ácidos nucleicos para inibição da expressão de c3 em uma célula
JP2023509870A (ja) 2019-12-24 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ
EP4081217A1 (fr) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Association pharmaceutique d'agents antiviraux ciblant le vhb et/ou un modulateur immunitaire pour le traitement du vhb
JP2023519246A (ja) 2020-03-26 2023-05-10 アローヘッド ファーマシューティカルズ インコーポレイテッド ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法
KR20230018429A (ko) 2020-05-27 2023-02-07 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 세포에서 cnnm4의 발현을 억제하기 위한 핵산
JP2023541170A (ja) 2020-09-15 2023-09-28 アローヘッド ファーマシューティカルズ インコーポレイテッド Ｚ－ａａｔタンパク質のレベルを低下させる方法
WO2022096424A1 (fr) 2020-11-04 2022-05-12 Universität Bern Acides nucléiques pour inhiber l'expression de pros1 dans une cellule
WO2022184852A1 (fr) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Acides nucléiques conjugués comprenant un phosphorodithioate pour inhiber l'expression génique dans une cellule
WO2022223557A1 (fr) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression de xdh dans une cellule
WO2022229150A1 (fr) 2021-04-27 2022-11-03 Silence Therapeutics Gmbh Petit arn interférent ciblant tmprss6 pour le traitement de troubles myéloprolifératifs
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
AU2022336157A1 (en) 2021-09-02 2024-03-14 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
ES2147216T3 (es) * 1993-09-01 2000-09-01 Akzo Nobel Nv Bisconjugados que comprenden dos sacaridos y un grupo de union.

Also Published As

Publication number Publication date
DK0655070T3 (da) 1999-04-26
DE69319912T2 (de) 1999-04-15
WO1994004545A1 (fr) 1994-03-03
DE69319912D1 (de) 1998-08-27
EP0655070A1 (fr) 1995-05-31
ATE168694T1 (de) 1998-08-15
JPH08502726A (ja) 1996-03-26
ES2122041T3 (es) 1998-12-16
AU4835593A (en) 1994-03-15
AU674160B2 (en) 1996-12-12
EP0655070B1 (fr) 1998-07-22
US5885968A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
NL9201440A (nl) Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU681010B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
EP0811011B1 (fr) Composes bioactifs conjugues a des hydrates de carbone
US5354853A (en) Phospholipid-saccharide conjugates
HUT74506A (en) Sialyl lewis-x analogues as inhibitors of cellular adhesion
JPH10507742A (ja) シアル酸／フコースベースの医薬
US20050187171A1 (en) Glycomimetic antagonists for both E-and P-selectins
CA2160100A1 (fr) Conjugues de carbohydrate, inhibiteurs de l'adherence cellulaire
WO1996005209A9 (fr) Medicaments a base d'acide sialique/de fucose
EP1763533B1 (fr) Antagoniste specifique pour e-selectines et p-selectines
WO1993010796A1 (fr) Derives de lactose et de lactosamine a substitution utilises comme inhibiteurs d'adhesion cellulaire
AU678373B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
AU595987B2 (en) Disaccharide derivatives
Marinier et al. Novel mimics of sialyl Lewis X: design, synthesis and biological activity of a series of 2-and 3-malonate substituted galactoconjugates
JP2535048B2 (ja) 新規ジサッカライド誘導体及びその塩
EP1549658B1 (fr) Composes a base de glucose presentant une affinite pour la selectine-p
JP2774429B2 (ja) 糖骨格を有する分枝鎖型誘導体
WO1999010359A2 (fr) Composes organiques
JP2951975B2 (ja) 抗腫瘍剤
JPH06199884A (ja) 新規糖脂質誘導体
WO1998055149A1 (fr) Utilisation de vecteurs medicamenteux pour produire des medicaments migrants dans les ganglions lymphatiques
WO1991008748A1 (fr) Synthese de saccharides recepteurs de rotavirus
IKAMI et al. Synthetic studies on sialoglycoconjugares. Part CVII. Synthetic Studies on Selectin Ligands/Inhibitors. Synthesis and Biological Evaluation of Sulfated and Phosphorylated. BETA.-D-Galacto-and Lactopyranosides Containing Fatty-Alkyl Residues of Different Carbon Chain Lengths.
JPH10152498A (ja) 糖脂質誘導体、それを有効成分とする免疫抑制剤およびその製造用中間体
Wright Synthesis of glycoconjugates affecting cell adhesion

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed